CASI Pharmaceuticals (CASIF) EPS (Weighted Average and Diluted) (2023 - 2025)
CASI Pharmaceuticals (CASIF) reported EPS (Weighted Average and Diluted) of -$4.16 for Q4 2025, down 363.38% on a YoY basis from $1.58 in Q4 2024, and down 509.98% quarter-over-quarter from -$0.68 in Q1 2025.
CASI Pharmaceuticals (CASIF) EPS (Weighted Average and Diluted) (2023 - 2025) Analysis & Trends
CASI Pharmaceuticals has reported EPS (Weighted Average and Diluted) for 3 years, with the latest figure at -$4.16 in Q4 2025.
- For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) fell 363.38% year-over-year to -$4.16; the trailing twelve-month figure through Dec 2025 stood at -$4.16 (down 363.38% YoY), and the FY2025 full-year result was -$2.59, down 1.17% from the prior year.
- EPS (Weighted Average and Diluted) for Q4 2025 stood at -$4.16, down from -$0.68 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $1.21 in Q4 2023, with the low at -$4.16 in Q4 2025.
- Historically, EPS (Weighted Average and Diluted) has averaged -$1.05 across 3 years, with a median of -$0.72 in 2024.
- The largest YoY upside for EPS (Weighted Average and Diluted) was 5.3% in 2025 against a maximum downside of 363.38% in 2025.
- CASI Pharmaceuticals' EPS (Weighted Average and Diluted) stood at $1.21 in 2023, then plunged by 174.49% to -$0.9 in 2024, then plunged by 363.38% to -$4.16 in 2025.
- The last three EPS (Weighted Average and Diluted) figures came in at -$4.16 (Q4 2025), -$0.68 (Q1 2025), and -$0.9 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 821,726.73 Bn | 821,726.69 Bn | - | - |
| 2 | Belite Bio | 57,768.00 Bn | 57,768.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 16,655.88 Bn | 16,655.88 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,540.00 Bn | 3,539.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,526.26 Bn | 1,526.24 Bn | - | - |
| 6 | Akari Therapeutics | 1,520.09 Bn | 1,520.09 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 223.87 Bn | 223.87 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.47 Bn | 107.23 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.22 Bn | 91.22 Bn | - | -0.61 |
| 10 | CASI Pharmaceuticals | - | - | 3.69 Mn | -4.16 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -4.16 |
| Mar 31, 2025 | -0.68 |
| Dec 31, 2024 | -0.90 |
| Mar 31, 2024 | -0.72 |
| Dec 31, 2023 | 1.21 |